Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin

Trial Profile

Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs BMS 986165 (Primary) ; Rosuvastatin
  • Indications Autoimmune disorders
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 13 Apr 2017 Status changed from recruiting to completed.
    • 09 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top